AuroBlog - Aurous Healthcare Clinical Trials blog
DECEMBER 17, 2023
Sickness in pregnancy, or hyperemesis gravidarum, is common and is thought to affect seven out of ten women at some time in their pregnancy. But, until recently, very little has been known about why it happens.
BioSpace
DECEMBER 17, 2023
The agency is investigating reports of secondary blood cancers in patients who have received certain CAR T cell therapies, but experts say the risk is low and is outweighed by the terminal nature of some cancers.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
AuroBlog - Aurous Healthcare Clinical Trials blog
DECEMBER 17, 2023
More needs to be done in the Asian diabetic population to design a more socially and culturally adaptable lifestyle intervention, according to Dr. Hema Venkatraman, consultant endocrinologist and medical advisor, Practo Transform. Dr Venkatraman further informed that diabetes remission as a diabetes management pathway is a relatively new concept.
BioSpace
DECEMBER 17, 2023
There is no evidence that the lapses have harmed patients who received Spikevax or clinical trial participants who received investigational shots.
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
JAMA Internal Medicine
DECEMBER 17, 2023
This systematic review and meta-analysis of randomized clinical trials assesses the association of toothbrushing with hospital-acquired pneumonia, mortality, length of stay, duration of mechanical ventilation, and use of antibiotics in hospitalized patients.
pharmaphorum
DECEMBER 17, 2023
Bristol-Myers Squibb has abandoned a bid to extend the indications of its combination of PD-1 inhibitor Opdivo and LAG-3 inhibitor relatlimab into colorectal cancer after it failed the phase 3 RELATIVITY-123 trial.
Clinical Research Informer brings together the best content for clinical researchers from the widest variety of industry thought leaders.
JAMA Internal Medicine
DECEMBER 17, 2023
This Viewpoint discusses tactics by corporations to criticize scientific research that may be unfavorable to their industries, recently including the spinal cord stimulator industry.
BioSpace
DECEMBER 17, 2023
The new fund brings Pivotal bioVenture Partners’ total capital to $689 million, which the venture capital firm intends to pump into young biotechs developing “innovative and impactful therapeutics.
Crucial Data Soutions
DECEMBER 17, 2023
Reno, NV, December 18, 2023 – Crucial Data Solutions (CDS), the only SaaS platform provider to empower customer-driven global clinical. The post Crucial Data Solutions Recognized as a Major Contender in Everest Group’s Decentralized Clinical Trial Platforms PEAK Matrix® Assessment 2023 appeared first on Crucial Data Solutions.
BioSpace
DECEMBER 17, 2023
As CAR T cell therapies attract significant biopharma investment, experts say there is plenty of space in the growing market for both treatments that use patients’ own cells and for those that rely on donor cells.
Drug Patent Watch
DECEMBER 17, 2023
This chart shows the drug companies with the most supplementary protection certificates (SPCs). SPCs are used in European Union and select others to encourage pharmaceutical innovation by compensating for the… The post Which pharmaceutical companies have supplementary protection certificates in the most countries? appeared first on DrugPatentWatch - Make Better Decisions.
BioSpace
DECEMBER 17, 2023
Following a U.S. appeals court decision, the company said it is preparing to divest GRAIL through a third-party sale or capital markets transaction.
Drug Patent Watch
DECEMBER 17, 2023
Dasatinib is the generic ingredient in two branded drugs marketed by Apotex and Bristol Myers Squibb and is included in three NDAs. There are two patents protecting this compound. Drug… The post New tentative approval for Teva Pharms drug dasatinib appeared first on DrugPatentWatch - Make Better Decisions.
BioSpace
DECEMBER 17, 2023
BMS will halt a trial investigating the Opdulag combination in colorectal cancer after determining that it would not hit its primary endpoint.
Advertisement
White paper that delves into the complex topic of Decentralized Clinical Trials and how to master them within the confines of FDA Regulations
Drug Patent Watch
DECEMBER 17, 2023
Icosapent ethyl is the generic ingredient in two branded drugs marketed by Apotex, Dr Reddys, Hikma, Strides Pharma, Teva Pharms Usa, Zydus, and Amarin Pharms and, and is included in… The post New tentative approval for Ascent Pharms drug icosapent ethyl appeared first on DrugPatentWatch - Make Better Decisions.
BioSpace
DECEMBER 17, 2023
The year may be coming to a close, but there's no holiday break for the FDA, which will release five regulatory verdicts over the next two weeks.
Drug Patent Watch
DECEMBER 17, 2023
VENTOLIN HFA (albuterol sulfate) Glaxosmithkline Patent: 7,832,351 Expiration: Dec 19, 2023 See More … For more information on how DrugPatentWatch can help with your pharmaceutical business intelligence needs, contact admin@DrugPatentWatch.com… The post Drug Patent Expirations for the Week of December 17, 2023 appeared first on DrugPatentWatch - Make Better Decisions.
BioSpace
DECEMBER 17, 2023
While the candidate was effective in Phase III results, Point’s stock price fell following the announcement.
Crucial Data Soutions
DECEMBER 17, 2023
Reno, NV, December 18, 2023 – Crucial Data Solutions (CDS), the only SaaS platform provider to empower customer-driven global clinical. The post Crucial Data Solutions Recognized as a Major Contender in Everest Group’s Decentralized Clinical Trial Platforms PEAK Matrix® Assessment 2023 appeared first on Crucial Data Solutions.
Pharma in Brief
DECEMBER 17, 2023
On December 4, 2023, the Federal Court held that a patent claiming a formulation of adalimumab, a monoclonal antibody used to treat autoimmune diseases, is valid and is being infringed by a biosimilar product. However, the Court refused to issue an injunction removing the infringing product from the Canadian market, finding that it was not in the public interest to force patients to switch to another biosimilar product.
Expert insights. Personalized for you.
246 
Let's personalize your content